{"id":12018,"date":"2025-03-14T00:44:31","date_gmt":"2025-03-13T23:44:31","guid":{"rendered":"https:\/\/valintermed.com\/?p=12018"},"modified":"2025-03-14T00:44:31","modified_gmt":"2025-03-13T23:44:31","slug":"medulloblastoma","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/medulloblastoma\/","title":{"rendered":"Medulloblastoma"},"content":{"rendered":"
<\/div>\n

Medulloblastoma is a highly aggressive neuroectodermal tumor that occurs primarily in the cerebellum. It accounts for approximately 20% of all primary brain tumors in children and is usually diagnosed in children between the ages of 3 and 8. However, medulloblastoma can also occur in adults, although this is much less common. The tumor is characterized by rapid growth and the ability to metastasize to the spinal cord and other parts of the central nervous system, making it potentially dangerous. Medulloblastomas are classified based on molecular subtypes, which have different prognoses and treatment options. The main symptoms are headaches, nausea, loss of coordination, and behavioral changes, which generally necessitates early diagnosis and a comprehensive approach to the treatment of this disease.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n